17.29
-0.08(-0.46%)
Currency In USD
Address
6 Tide Street
Boston, MA 02210
United States of America
Phone
857 520 9158
Website
Sector
Healthcare
Industry
Biotechnology
Employees
177
First IPO Date
October 29, 2021
| Name | Title | Pay | Year Born |
| Mr. Dipal Doshi | Chief Executive Officer & Director | 968,213 | 1976 |
| Dr. Natarajan Sethuraman Ph.D. | President of Research & Development | 694,299 | 1962 |
| Mr. Nathan J. Dowden | President & Chief Operating Officer | 694,299 | 1971 |
| Ms. Karla MacDonald | Chief Corporate Affairs Officer | 0 | N/A |
| Mr. Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel | 0 | N/A |
| Mr. Kory James Wentworth CPA | Chief Financial Officer & Treasurer | 0 | 1979 |
| Ms. Kerry Robert M.S. | Senior Vice President of People | 0 | N/A |
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.